U.S. markets closed

Sona Nanotech Inc. (SNANF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.4344+0.0544 (+3.94%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3800
Open1.3300
BidN/A x N/A
AskN/A x N/A
Day's Range1.3100 - 1.4345
52 Week Range0.6020 - 11.9800
Volume11,964
Avg. Volume23,088
Market Cap89.716M
Beta (5Y Monthly)-3.35
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Sona to Commence Clinical Trial for COVID-19 Rapid Saliva Test
    Newsfile

    Sona to Commence Clinical Trial for COVID-19 Rapid Saliva Test

    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021. Halifax, Nova Scotia--(Newsfile Corp. - April 22, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests is pleased to announce that it has received research ethics board approval for its clinical trial of the ...

  • Sona Secures Clinical Trial Authorization and Hospital Partner
    Newsfile

    Sona Secures Clinical Trial Authorization and Hospital Partner

    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021. Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a developer of rapid, point-of-care diagnostic tests is pleased to announce that it has been granted Health Canada Investigational Testing Authorization for a clinical trial ...

  • Sona Establishes an At-The-Market Common Share Offering
    Newsfile

    Sona Establishes an At-The-Market Common Share Offering

    Halifax, Nova Scotia--(Newsfile Corp. - April 9, 2021) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests announces that pursuant to an equity distribution agreement (the "Equity Distribution Agreement") with Canaccord Genuity Corp., the Company may, from time to time, sell up to $10 million of common shares ("Common Shares") in the capital of the Company (the "ATM Offering"). The Company intends to ...